| Document Date: 2014-04-28 15:04:32
Open Document File Size: 357,11 KBShare Result on Facebook
City La Jolla / / Continent Europe / / IndustryTerm 2a protocol / cross / / MedicalCondition active disease / IBD / Clinical sepsis / bacteremia / strain / inflammation / bacteremia/sepsis / Severe Active Ulcerative Colitis / systemic opportunistic infections / different colitis / / MedicalTreatment Surgery / / Organization FDA / National Institute of Health / Recombinant DNA Advisory Committee / / Person Pieter Rottiers / W. Sandborn / William J. Sandborn / B. Coulie / L. Steidler / Lothar Steidler / Bernard Coulie / P. Rottiers / / Position Vice President R&D / CEO / PhD Vice President / PhD Vice President Technology / / Product Prednisone / Current capsule / Concomitant medication / / Technology alpha / Phase 2a protocol / Recombinant DNA / / URL www.clinicaltrialsregister.eu / www.clinicaltrials.gov / /
SocialTag |
Protocol #[removed]Recombinant DNA Advisory Committee (RAC) December 5, 2013 Presenters: • Dr. William J. Sandborn, MD (Study PI) UC San Diego Health System, La Jolla, CA